Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May:66 Suppl 4:iv7-iv15.
doi: 10.1093/jac/dkr072.

Linezolid pharmacokinetics and pharmacodynamics in clinical treatment

Matthew S Dryden  1
Affiliations
Review

Linezolid pharmacokinetics and pharmacodynamics in clinical treatment

Matthew S Dryden. J Antimicrob Chemother. 2011 May.

Abstract

Linezolid has been widely used in the treatment of Gram-positive infections for more than a decade. It is unique amongst antibiotics active against most multiply-resistant Gram-positive bacteria in that there is an oral preparation with 100% bioavailability and an extensive volume of distribution. This review examines pharmacokinetic data relating to linezolid use in different patient groups (obesity, enteral feeding, renal failure, neonates, and paediatrics) and in different clinical conditions (sepsis syndrome, skin and soft tissue infection, diabetic foot infection, pneumonia, bone and joint infection, infection of the central nervous system, eye infection, and neutropenic sepsis).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • New developments in the management of severe skin and deep skin structure infections - focus on tedizolid.
    Durkin MJ, Corey GR. Durkin MJ, et al. Ther Clin Risk Manag. 2015 May 22;11:857-62. doi: 10.2147/TCRM.S64553. eCollection 2015. Ther Clin Risk Manag. 2015. PMID: 26045667 Free PMC article. Review.
  • Physicochemical Compatibility and Stability of Linezolid with Parenteral Nutrition.
    Tomczak S, Stawny M, Dettlaff K, Kieliszek M, Słomińska D, Jelińska A. Tomczak S, et al. Molecules. 2019 Mar 29;24(7):1242. doi: 10.3390/molecules24071242. Molecules. 2019. PMID: 30934964 Free PMC article.
  • Clinical standards for the dosing and management of TB drugs.
    Alffenaar JWC, Stocker SL, Forsman LD, Garcia-Prats A, Heysell SK, Aarnoutse RE, Akkerman OW, Aleksa A, van Altena R, de Oñata WA, Bhavani PK, Van't Boveneind-Vrubleuskaya N, Carvalho ACC, Centis R, Chakaya JM, Cirillo DM, Cho JG, D Ambrosio L, Dalcolmo MP, Denti P, Dheda K, Fox GJ, Hesseling AC, Kim HY, Köser CU, Marais BJ, Margineanu I, Märtson AG, Torrico MM, Nataprawira HM, Ong CWM, Otto-Knapp R, Peloquin CA, Silva DR, Ruslami R, Santoso P, Savic RM, Singla R, Svensson EM, Skrahina A, van Soolingen D, Srivastava S, Tadolini M, Tiberi S, Thomas TA, Udwadia ZF, Vu DH, Zhang W, Mpagama SG, Schön T, Migliori GB. Alffenaar JWC, et al. Int J Tuberc Lung Dis. 2022 Jun 1;26(6):483-499. doi: 10.5588/ijtld.22.0188. Int J Tuberc Lung Dis. 2022. PMID: 35650702 Free PMC article.
  • Tuberculosis and pharmacological interactions: A narrative review.
    Riccardi N, Canetti D, Rodari P, Besozzi G, Saderi L, Dettori M, Codecasa LR, Sotgiu G. Riccardi N, et al. Curr Res Pharmacol Drug Discov. 2020 Dec 15;2:100007. doi: 10.1016/j.crphar.2020.100007. eCollection 2021. Curr Res Pharmacol Drug Discov. 2020. PMID: 34909643 Free PMC article. Review.
  • Linezolid: a review of its properties, function, and use in critical care.
    Hashemian SMR, Farhadi T, Ganjparvar M. Hashemian SMR, et al. Drug Des Devel Ther. 2018 Jun 18;12:1759-1767. doi: 10.2147/DDDT.S164515. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 29950810 Free PMC article. Review.
See all "Cited by" articles

MeSH terms